# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life--People with Undia...
Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.5...
https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...
-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and stati...
Leerink Partners analyst Rudy Li initiates coverage on Mind Medicine (NASDAQ:MNMD) with a Outperform rating and announces Pr...
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday.
U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday.